BioLineRx Income Statement (2023-2025) | BLRX

Income Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 0.93M1.34M0.84M-0.93M6.86M5.39M4.94M11.75M0.26M0.30M0.43M
Cost of Revenue 3.87M5.60M8.13M7.66M6.34M6.42M5.55M5.29M0.03M0.07M0.08M
Gross Profit 5.40M4.50M4.12M5.66M0.22M0.23M0.34M
Operating items
Research & Development -3.68M-3.01M-2.73M-3.10M-2.49M-2.23M-2.56M-1.86M-1.62M-2.33M-1.72M
Selling, General & Administrative -1.30M-1.30M-1.50M-2.21M-1.39M-1.63M-1.39M-1.92M-0.99M-0.21M-0.83M
Operating Expenses -4.98M-4.31M-4.23M-5.31M-3.88M-3.85M-3.96M-3.78M-2.61M-2.54M-2.55M
Operating Income -8.86M-9.91M-12.36M-18.57M-4.82M-5.77M-5.39M-4.43M-2.39M-2.30M-2.21M
EBIT -8.86M-9.91M-12.36M-18.57M-4.82M-5.77M-5.39M-4.43M-2.39M-2.30M-2.21M
Net income details
EBT -7.93M-8.58M-11.52M-19.50M-3.89M-3.69M-3.76M0.05M-1.97M-2.03M-1.90M
Profit After Tax -12.16M-18.55M-16.02M-1.42M-1.42M-1.42M-1.42M-1.42M-1.42M-1.42M-1.42M
Income from Continuing Operations -7.93M-8.58M-11.52M-19.50M-3.89M-3.69M-3.76M0.05M-1.97M-2.03M-1.90M
Consolidated Net Income -7.93M-8.58M-11.52M-19.50M-3.89M-3.69M-3.76M0.05M-1.97M-2.03M-1.90M
Income towards Parent Company -7.93M-8.58M-11.52M-19.50M-3.89M-3.69M-3.76M0.05M-1.97M-2.03M-1.90M
Net Income towards Common Stockholders -7.93M-8.58M-11.52M-19.50M-3.89M-3.69M-3.76M0.05M-1.97M-2.03M-1.90M
Additional items
EPS (Basic) -0.01-0.01-0.01-0.020.000.000.000.000.000.000.00
Shares Outstanding (Weighted Average) 922.96M922.96M922.96M929.06M1,086.59M1,086.59M1,197.58M1,199.49M2,232.60M2,232.60M2,369.69M
EBITDA -12.16M18.55M-12.36M-18.57M-0.70M0.48M-5.82M-4.43M5.13M-3.94M-0.98M
Interest Expenses -0.93M-1.34M-0.84M0.93M-0.93M-2.08M-1.62M-4.48M-0.42M-0.28M-0.30M